CRON Cronos Group Inc.

CIK 0001656472 50 ready 8-Ks latest August 6, 2026, 7:31 AM ET RSS · JSON

Activity: NORMAL 2 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing August 7, 2026, 5:03 PM ET

Top materiality 0.90

Event mix earnings ×21 · other_material ×11 · leadership ×11

Sentiment 15 pos · 12 neg · 23 neu

Latest earnings reported 2026-Q2

Executive change recent →

Recent 8-K filings for CRON

Highest-materiality recent filing

Cronos to restate Q2 2021 financials; at least $220M impairment in U.S. reporting unit

November 9, 2021, 6:59 PM ET other material materiality 0.90 negative item 4.02 item 9.01

Previously issued unaudited interim financial statements for Q2 2021 should no longer be relied upon.
Impairment charge of not less than $220M on goodwill and indefinite-lived intangible assets in U.S. reporting unit.

Read filing →

August 6, 2026, 7:31 AM ET earnings materiality 0.85 positive item 2.02 item 9.01

Cronos Q2 net revenue up 58% YoY to $53M; record Adjusted EBITDA of $13.1M

Net revenue $53.0M (+58% YoY); organic constant-currency growth 51%.
May 11, 2026, 7:59 PM ET earnings materiality 0.75 positive item 1.01 item 2.02 item 8.01 item 9.01 ◈ Earnings Releases

Cronos Q1 net revenue up 40% to $45.2M; authorizes $50M share buyback; CanAdelaar close extended to Sep 9

Net revenue $45.2M (+40% YoY); net income $15.7M (+103%); adjusted EBITDA $5.1M (+122%).
February 26, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Cronos Group Q4 2025 net revenue $44.5M (+47% YoY); net loss $0.5M vs income $43.9M

Q4 net revenue $44.5M, up 47% YoY; full-year net revenue $146.6M, up 25% YoY.
December 9, 2025, 6:59 PM ET M&A materiality 0.75 positive item 1.01 item 7.01 item 9.01 ◈ Material Agreements

Cronos to acquire CanAdelaar, Dutch cannabis market leader, for US$67M upfront plus earnouts

Upfront consideration of €57.5M (US$67.0M) cash, plus earnout of 0.5x normalized EBITDA in 2026 and 2027.
November 6, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Cronos Group Q3 net revenue $36.3M (+6% YoY); record Adj. EBITDA of $5.7M

Net revenue $36.3M, up 6% YoY; gross profit $18.3M (50% margin) vs $3.6M (11%) a year ago.
August 7, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 5.02 item 9.01

Cronos Q2 net revenue $33.5M (+21% YoY); adjusted EBITDA turns positive to $1.7M

Net revenue $33.5M, up 21% YoY; adjusted gross margin improved to 43% from 23%.
May 8, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 8.01 item 9.01

Cronos Q1 net revenue $32.3M (+28% YoY), net income $7.7M; authorizes $50M buyback

Net revenue $32.3M (+28% YoY); net income $7.7M vs loss of $2.5M in Q1 2024.
March 19, 2025, 7:59 PM ET leadership materiality 0.65 neutral item 5.02 item 9.01 ◈ executive_change ×2

Cronos Group appoints Anna Shlimak as CFO; James Holm departs

Anna Shlimak appointed CFO effective March 19, 2025; James Holm ceases as CFO but remains employed through April 18, 2025.
February 27, 2025, 6:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

Cronos Group Q4 revenue up 27% YoY to $30.3M; reports net income of $43.9M vs prior year loss

Q4 net revenue $30.3M (+27% YoY); full-year revenue $117.6M (+35% YoY).
November 12, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Cronos Group Q3 revenue up 38% to $34.3M; Spinach becomes #1 cannabis brand in Canada

Net revenue $34.3M, +38% YoY; net income $7.3M vs loss of $1.6M in Q3 2023.
August 8, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Cronos Group Q2 net revenue rises 46% to $27.8M; net loss widens, Adj EBITDA improves

Net revenue $27.8M, up 46% YoY; gross profit $6.3M (+103%).
June 25, 2024, 7:59 PM ET debt materiality 0.70 neutral item 1.01 item 8.01 item 9.01

Cronos ups GrowCo credit by C$70M to C$175M, secures supply rights for Phase 2

Credit Agreement adds C$70M Term Loan B for Phase 2 cannabis facility; total facility now C$175M.
May 9, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

Cronos Q1 revenue up 30% YoY to $25.3M; net loss narrows; guidance reaffirmed

Net revenue $25.3M (+30% YoY); gross profit $4.5M (+53%); net loss improved to $(2.5M) from $(18.0M).
April 17, 2024, 7:59 PM ET other material materiality 0.70 negative item 4.01 item 9.01

Cronos Group auditor KPMG exits; will not seek re-appointment for 2024 audit

KPMG notified Cronos it will not stand for re-appointment for 2024 audit due to KPMG's decision to cease auditing cannabis companies.
April 3, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 8.01 item 9.01 ◈ executive_change

Cronos Group appoints Adam Wagner as Head of Cronos Israel; Gorelik becomes Chairman

Ran Gorelik steps down as GM of Cronos Israel effective April 2, 2024; becomes Chairman through April 1, 2026.
February 29, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Cronos Group Q4 net revenue up 9% YoY; net loss improves to $45M; cash balance $862M

Q4 net revenue $23.9M (+9% YoY); full-year net revenue $87.2M (+1% YoY).
November 27, 2023, 6:59 PM ET other material materiality 0.65 positive item 1.01 item 7.01 item 9.01 ◈ Material Agreements

Cronos Group enters sale-leaseback of Stayner facility for C$23M cash

Cronos subsidiary agrees to sell Peace Naturals Campus to Future Farmco Canada for C$23M.
November 8, 2023, 6:59 PM ET earnings materiality 0.65 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Cronos Q3 net revenue $24.8M (+22% YoY); net loss narrows to $1.6M from $33.1M

Net revenue $24.8M (+22% YoY); constant currency $26.0M (+27% YoY). Grows driven by Canadian flower, extract sales.
August 8, 2023, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

Cronos Group Q2 revenue down 12% to $19M, withdraws FY2023 guidance; announces facility wind-down

Q2 net revenue $19.0M (-12% YoY); net loss improved to $(5.7)M from $(17.5)M YoY.
May 31, 2023, 7:59 PM ET other material materiality 0.70 positive item 7.01 item 9.01

Cronos Group to exit U.S. hemp CBD ops, raise savings target to $20-25M

Will wind down U.S. hemp-derived CBD operations by end of Q2 2023; expects up to $1.8M in exit costs.
May 9, 2023, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01 ◈ Earnings Releases

Cronos Q1 revenue $20.1M (-20% YoY); gross margin 12%; targets cash flow positive 2024

Net revenue $20.1M, down 20% YoY; gross margin 12% vs 28%; net loss $(19.3)M improved from $(32.7)M.
February 28, 2023, 6:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases ×2

Cronos Group FY2022 revenue $91.9M (+23% YoY); net loss narrows to $168.7M; Spinach #1 edible brand in Canada

Full-year 2022 net revenue $91.9M, up 23% YoY; Israel revenue up 128% (constant currency +137%).
December 19, 2022, 6:59 PM ET other material materiality 0.70 neutral item 8.01 item 9.01

Altria relinquishes warrant to buy 84.2M Cronos shares at C$19 for no consideration

Altria abandoned warrant for up to 84,243,223 Cronos common shares at C$19.00 per share, effective Dec 16, 2022, for no consideration.
November 14, 2022, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01 ◈ executive_change ×2

Cronos Group names James Holm as CFO effective Nov 14, 2022; Robert Madore departs

Robert Madore ceased as CFO; receives one-year base salary severance, pro-rated bonus, and accelerated vesting of 37,500 RSUs and 450,000 options.
November 7, 2022, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01 ◈ Earnings Releases

Cronos Q3 revenue up 3% to $20.9M; net loss $36.9M vs prior year income; Jeff Jacobson named CGO

Consolidated net revenue $20.9M, up 3% YoY; constant currency +7% to $21.8M.
October 25, 2022, 7:59 PM ET regulatory materiality 0.75 negative item 8.01 item 9.01

Cronos settles SEC and OSC investigations over accounting errors; pays C$1.34M, loses WKSI status

SEC order imposes cease-and-desist; no monetary penalty but Cronos loses WKSI status for 3 years and Regulation A/D exemption use for 5 years.
August 9, 2022, 7:59 PM ET earnings materiality 0.65 negative item 2.02 item 9.01

Cronos Q2 net revenue $23.1M (+48% YoY); net loss narrows to $20.3M from $179.4M

Consolidated net revenue $23.1M, up 48% YoY; Rest of World segment $21.6M (+61%); U.S. $1.5M (-34%).
May 10, 2022, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

Cronos Q1 revenue up 99% YoY to $25M; net loss narrows; Gorenstein returns as CEO

Consolidated net revenue $25.0M (+99% YoY); Israel net revenue $9.1M (+263% YoY).
March 21, 2022, 7:59 PM ET leadership materiality 0.70 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Cronos Group founder Mike Gorenstein returns as CEO, replaces retiring Kurt Schmidt

Gorenstein appointed President and CEO effective March 21, 2022; continues as Chairman.
March 1, 2022, 6:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Cronos Group Q4 revenue $25.8M (+51% YoY), net loss $133.9M; plans Stayner facility exit

Net revenue $25.8M in Q4 (+51% YoY); full-year revenue $74.4M (+59% YoY).
February 18, 2022, 6:59 PM ET earnings materiality 0.85 negative item 2.02 item 9.01

Cronos restates Q2 2021 with $236M impairment; Q3 rev up 80% to $20.4M, adj EBITDA loss widens

Restated Q2 2021 with $236.1M impairment on goodwill and intangibles in U.S. reporting unit; no cash impact.
November 23, 2021, 6:59 PM ET regulatory materiality 0.60 negative item 3.01 item 9.01

Cronos Group receives Nasdaq delinquency notice for late Q3 10-Q; MCTO issued

Nasdaq notice, dated Nov 16, 2021, cites non-compliance with Listing Rule 5250(c)(1) for untimely Form 10-Q.
November 9, 2021, 6:59 PM ET other material materiality 0.90 negative item 4.02 item 9.01

Cronos to restate Q2 2021 financials; at least $220M impairment in U.S. reporting unit

Previously issued unaudited interim financial statements for Q2 2021 should no longer be relied upon.
August 6, 2021, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Cronos Group Q2 net revenue $15.6M (+58% YoY); gross loss expands to $15.8M; invests $110M in PharmaCann

Net revenue $15.6M, up 58% YoY; ROW segment $13.4M (+74%) driven by Canada adult-use and Israel medical.

Executive changes

Departed

James Holm

Chief Financial Officer

CRON · Cronos Group Inc.

Effective: 2025-03-19
Successor: Anna Shlimak
Filed: March 19, 2025, 7:59 PM ET

As of the Effective Date, James Holm will no longer serve as the Company’s Chief Financial Officer.

Appointed

Anna Shlimak

Chief Financial Officer

CRON · Cronos Group Inc.

Effective: 2025-03-19
Filed: March 19, 2025, 7:59 PM ET

Effective as of March 19, 2025 (the “Effective Date”), Cronos Group Inc. (the “Company”) has appointed Anna Shlimak, the Company’s Chief Strategy Officer, as the Company’s Chief Financial Officer.

Role change

Ran Gorelik

Chairman of Cronos Israel

CRON · Cronos Group Inc.

Effective: 2024-04-02
Filed: April 3, 2024, 7:59 PM ET

pursuant to which Mr. Gorelik will become Chairman of Cronos Israel and will no longer serve as General Manager (Cronos Israel).

Appointed

James McGinness

Vice President, Controller

CRON · Cronos Group Inc.

Effective: 2023-05-22
Filed: May 19, 2023, 7:59 PM ET

On May 18, 2023, Cronos Group Inc. (the “Company”) appointed James McGinness to the position of Vice President, Controller, which includes serving as the Company’s principal accounting officer, effective as of May 22, 2023.

Departed

Carlos Cortez

Vice President, Controller

CRON · Cronos Group Inc.

Effective: 2023-05-22
Successor: James McGinness
Filed: May 19, 2023, 7:59 PM ET

On May 18, 2023, the Company determined that Carlos Cortez, the Company’s Vice President, Controller, will no longer serve as the Company’s principal accounting officer as of May 22, 2023 and will separate from the Company, effective as of June 16, 2023.

Departed

Robert Madore

Chief Financial Officer

CRON · Cronos Group Inc.

Effective: 2022-11-14
Filed: February 13, 2023, 6:59 PM ET

As previously disclosed, effective as of November 14, 2022, Robert Madore ceased to serve as Chief Financial Officer of Cronos Group Inc.

Appointed

James Holm

Chief Financial Officer

CRON · Cronos Group Inc.

Effective: 2022-11-14
Filed: November 14, 2022, 6:59 PM ET

the Company has appointed James Holm as Chief Financial Officer of the Company.

Departed

Robert Madore

Chief Financial Officer

CRON · Cronos Group Inc.

Effective: 2022-11-14
Successor: James Holm
Filed: November 14, 2022, 6:59 PM ET

Robert Madore will no longer serve as Chief Financial Officer of Cronos Group Inc.

Departed

John Griese

Senior Vice President, Head of Operations (North America)

CRON · Cronos Group Inc.

Effective: 2022-10-18
Filed: October 18, 2022, 7:59 PM ET

Effective as of the close of business on October 18, 2022, John Griese will no longer serve as Senior Vice President, Head of Operations (North America) of Cronos Group Inc.

Departed

Kurt Schmidt

President and Chief Executive Officer

CRON · Cronos Group Inc.

Effective: 2022-03-21
Successor: Michael Gorenstein
Filed: March 21, 2022, 7:59 PM ET

Kurt Schmidt retired from the positions of President and Chief Executive Officer of Cronos Group.

Appointed

Michael Gorenstein

President and Chief Executive Officer

CRON · Cronos Group Inc.

Effective: 2022-03-21
Filed: March 21, 2022, 7:59 PM ET

appointed Michael Gorenstein as President and Chief Executive Officer of Cronos Group, effective as of March 21, 2022

Appointed

John Griese

Senior Vice President, Head of Operations (North America)

CRON · Cronos Group Inc.

Effective: 2022-01-10
Filed: January 10, 2022, 6:59 PM ET

On January 10, 2022, Cronos Group Inc. (the “Company”) appointed John Griese as Senior Vice President, Head of Operations (North America) of the Company.

Earnings & guidance

2026-Q2 EPS reported $0.12 filing →

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event earnings

15 positive 12 negative 23 neutral

source · CRON on sec.gov